FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3036364440> ?p ?o ?g. }

• W3036364440 endingPage "1159" @default.
• W3036364440 startingPage "1148" @default.
• W3036364440 abstract "In recurrent ovarian cancer, poly(ADP-ribose) polymerase (PARP)-inhibiting agents have transformed the treatment of platinum-sensitive disease. New data support use of PARP inhibitors earlier in the treatment algorithm.We review results from recent phase III trials evaluating PARP inhibitors as treatment and/or maintenance therapy for patients with newly diagnosed ovarian cancer. We discuss the efficacy and safety of these agents in the all-comer and biomarker-selected populations studied in clinical trials, and compare the strengths and limitations of the various trial designs. We also consider priorities for future research, with a particular focus on patient selection and future regimens for populations with high unmet need.Four phase III trials (SOLO-1, PAOLA-1/ENGOT-OV25, PRIMA/ENGOT-OV26 and VELIA/GOG-3005) demonstrated remarkable improvements in progression-free survival with PARP inhibitor therapy (olaparib, niraparib or veliparib) for newly diagnosed ovarian cancer. Differences in trial design (treatment and/or maintenance setting; single agent or combination; bevacizumab or no bevacizumab), patient selection (surgical outcome, biomarker eligibility, prognosis) and primary analysis population (intention-to-treat, BRCA mutated or homologous recombination deficiency positive) affect the conclusions that can be drawn from these trials. Overall survival data are pending and there is limited experience regarding long-term safety.PARP inhibitors play a pivotal role in the management of newly diagnosed ovarian cancer, which will affect subsequent treatment choices. Refinement of testing for patient selection and identification of regimens to treat populations that appear to benefit less from PARP inhibitors are a priority." @default.
• W3036364440 created "2020-06-25" @default.
• W3036364440 creator A5007606531 @default.
• W3036364440 creator A5009234043 @default.
• W3036364440 creator A5053409630 @default.
• W3036364440 creator A5066888430 @default.
• W3036364440 creator A5069337573 @default.
• W3036364440 creator A5079485962 @default.
• W3036364440 creator A5083659627 @default.
• W3036364440 date "2020-09-01" @default.
• W3036364440 modified "2023-10-11" @default.
• W3036364440 title "The forefront of ovarian cancer therapy: update on PARP inhibitors" @default.
• W3036364440 cites W2062802357 @default.
• W3036364440 cites W2096235803 @default.
• W3036364440 cites W2097265582 @default.
• W3036364440 cites W2111437716 @default.
• W3036364440 cites W2113122060 @default.
• W3036364440 cites W2135947389 @default.
• W3036364440 cites W2151509048 @default.
• W3036364440 cites W2329492928 @default.
• W3036364440 cites W2337360019 @default.
• W3036364440 cites W2467785194 @default.
• W3036364440 cites W2518728331 @default.
• W3036364440 cites W2528228811 @default.
• W3036364440 cites W2557666746 @default.
• W3036364440 cites W2558976494 @default.
• W3036364440 cites W2561432266 @default.
• W3036364440 cites W2589697688 @default.
• W3036364440 cites W2590203295 @default.
• W3036364440 cites W2737389832 @default.
• W3036364440 cites W2754327139 @default.
• W3036364440 cites W2771225985 @default.
• W3036364440 cites W2771566635 @default.
• W3036364440 cites W2772338061 @default.
• W3036364440 cites W2801496605 @default.
• W3036364440 cites W2802074519 @default.
• W3036364440 cites W2804007674 @default.
• W3036364440 cites W2804717005 @default.
• W3036364440 cites W2806903112 @default.
• W3036364440 cites W2807037141 @default.
• W3036364440 cites W2888002479 @default.
• W3036364440 cites W2891245632 @default.
• W3036364440 cites W2891719366 @default.
• W3036364440 cites W2896626889 @default.
• W3036364440 cites W2897430921 @default.
• W3036364440 cites W2901022488 @default.
• W3036364440 cites W2901506506 @default.
• W3036364440 cites W2906986535 @default.
• W3036364440 cites W2908112515 @default.
• W3036364440 cites W2913578326 @default.
• W3036364440 cites W2935541805 @default.
• W3036364440 cites W2939332654 @default.
• W3036364440 cites W2944623054 @default.
• W3036364440 cites W2954373146 @default.
• W3036364440 cites W2954849024 @default.
• W3036364440 cites W2954976904 @default.
• W3036364440 cites W2968820602 @default.
• W3036364440 cites W2970135300 @default.
• W3036364440 cites W2975141952 @default.
• W3036364440 cites W2976139792 @default.
• W3036364440 cites W2977309968 @default.
• W3036364440 cites W2977744611 @default.
• W3036364440 cites W2980322460 @default.
• W3036364440 cites W2984589472 @default.
• W3036364440 cites W2985223161 @default.
• W3036364440 cites W2991621188 @default.
• W3036364440 cites W2994977341 @default.
• W3036364440 cites W3008413445 @default.
• W3036364440 cites W3014455410 @default.
• W3036364440 cites W3023274953 @default.
• W3036364440 cites W4255106880 @default.
• W3036364440 doi "https://doi.org/10.1016/j.annonc.2020.06.004" @default.
• W3036364440 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32569725" @default.
• W3036364440 hasPublicationYear "2020" @default.
• W3036364440 type Work @default.
• W3036364440 sameAs 3036364440 @default.
• W3036364440 citedByCount "160" @default.
• W3036364440 countsByYear W30363644402020 @default.
• W3036364440 countsByYear W30363644402021 @default.
• W3036364440 countsByYear W30363644402022 @default.
• W3036364440 countsByYear W30363644402023 @default.
• W3036364440 crossrefType "journal-article" @default.
• W3036364440 hasAuthorship W3036364440A5007606531 @default.
• W3036364440 hasAuthorship W3036364440A5009234043 @default.
• W3036364440 hasAuthorship W3036364440A5053409630 @default.
• W3036364440 hasAuthorship W3036364440A5066888430 @default.
• W3036364440 hasAuthorship W3036364440A5069337573 @default.
• W3036364440 hasAuthorship W3036364440A5079485962 @default.
• W3036364440 hasAuthorship W3036364440A5083659627 @default.
• W3036364440 hasBestOaLocation W30363644401 @default.
• W3036364440 hasConcept C104317684 @default.
• W3036364440 hasConcept C121608353 @default.
• W3036364440 hasConcept C126322002 @default.
• W3036364440 hasConcept C143998085 @default.
• W3036364440 hasConcept C182979987 @default.
• W3036364440 hasConcept C185592680 @default.
• W3036364440 hasConcept C2776694085 @default.
• W3036364440 hasConcept C2777802072 @default.

• next